Hims & Hers Health (NYSE:HIMS) Trading 7.1% Higher – Here’s Why

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) traded up 7.1% during mid-day trading on Tuesday . The stock traded as high as $30.92 and last traded at $31.4240. Approximately 7,191,239 shares traded hands during mid-day trading, a decline of 70% from the average daily volume of 24,206,293 shares. The stock had previously closed at $29.35.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers continues to grow rapidly. Second-quarter revenue rose 38.2% year over year to $753.2 million, exceeding estimates, while the company added roughly 300,000 subscribers and raised full-year 2026 revenue guidance to $3.1 billion-$3.3 billion. Management also reported early benefits from its AI care platform, including lower support costs and cancellation rates. Hims and Hers scaling article
• Neutral Sentiment: CFO Oluyemi Okupe sold 29,277 shares for approximately $876,846, reducing his direct ownership by 11.01%. Because the transaction was executed under a pre-arranged Rule 10b5-1 plan, it may be less concerning than discretionary insider selling, although the sale can still weigh on investor sentiment. He retained 236,527 shares. SEC insider transaction filing
• Negative Sentiment: The principal overhang is legal exposure. The FTC alleges that Hims & Hers shared sensitive health information with advertising platforms and used unclear subscription-cancellation and prescription-billing practices. Multiple law firms have publicized a related securities class action covering investors who purchased shares between August 4, 2025, and July 29, 2026. The deadline to seek lead-plaintiff status is November 2, 2026, increasing potential legal costs, regulatory scrutiny and reputational risk. Hims and Hers securities class action article
• Negative Sentiment: Profitability is also troubling. Hims & Hers reported a quarterly loss of $0.37 per share versus expectations for a $0.05 loss, negative free cash flow of $68 million and approximately $81 million in acquisition, restructuring and FTC-related costs. Additional litigation expenses could further pressure earnings and cash flow. Hims and Hers stock analysis

Analyst Ratings Changes

HIMS has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft upped their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. Morgan Stanley boosted their price objective on Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. began coverage on Hims & Hers Health in a research note on Friday, September 11th. They issued a “neutral” rating and a $32.00 target price for the company. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Finally, TD Cowen lifted their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research note on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and a consensus price target of $32.43.

Hims & Hers Health Stock Down 6.6%

The business has a 50 day simple moving average of $29.69 and a 200 day simple moving average of $27.97. The company has a market capitalization of $6.63 billion, a price-to-earnings ratio of -45.13 and a beta of 2.42. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. During the same period in the previous year, the firm posted $0.17 earnings per share. The company’s quarterly revenue was up 38.2% compared to the same quarter last year. As a group, equities analysts predict that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total transaction of $398,226.53. Following the sale, the chief operating officer directly owned 456,660 shares of the company’s stock, valued at $12,964,577.40. This represents a 2.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 6,236 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $27.86, for a total transaction of $173,734.96. Following the sale, the insider directly owned 304,270 shares in the company, valued at approximately $8,476,962.20. The trade was a 2.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 128,684 shares of company stock valued at $3,731,869 over the last three months. 11.76% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cunning Capital Partners LP acquired a new position in Hims & Hers Health during the 4th quarter worth $1,110,000. Norges Bank purchased a new stake in Hims & Hers Health during the 4th quarter worth about $62,153,000. Virtu Financial LLC acquired a new stake in Hims & Hers Health in the 4th quarter valued at about $1,937,000. Louisiana State Employees Retirement System acquired a new stake in Hims & Hers Health in the 1st quarter valued at about $1,254,000. Finally, X Square Capital LLC boosted its stake in shares of Hims & Hers Health by 9.7% in the 4th quarter. X Square Capital LLC now owns 468,999 shares of the company’s stock valued at $15,228,000 after buying an additional 41,408 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.